Use of inhibitors of 24-hydroxylase in the treatment of cancer

Abstract

The present invention relates to a method of treating cancer in a subject. The method comprises administering to a subject suffering from cancer a therapeutically effective amount of a 24-hydroxylase inhibitor in combination with a second amount of a suitable cancer therapeutic. The 24-hydroxylase inhibitor can be coadministered with a chemotherapeutic agent, such an antitumor antibiotic (e.g., mitoxantrone or bleomycin), an alkylating agent (e.g., estramustine or melphalan), a plant alkaloid (e.g., taxenes such as paclitaxel or docetaxel or vinca alkaloids such as vincristine or vinblastine) or a combination thereof. In additional therapy, the 24-hydroxylase inhibitor can be coadministered as an adjuvant to radiation therapy, such as an external beam irradiation or a radioisotope therapy, such as radiopharmaceutical therapy. Further, the 24-hydroxylase inhibitor can be coadministered as part of a combination therapy that includes hormonal ablation.

Dependencies are inferred from the claim text.